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Abstract
Background: The lung is divided into two major compartments: the alveolar space and the
parenchyma. The alveolar macrophages are the first line of leukocytes in the lung taking up
incoming microbes or microbial antigens whereas the parenchymal dendritic cells (DCs) are
believed to be the sole potent antigen presenting cells (APCs) in the lung. Both resting alveolar
macrophages and parenchymal DCs express CD11c. Several important questions remain to be
elucidated: 1] to which extent the alveolar space and lung parenchymal CD11c+ APCs differ in their
phenotype and ability to activate naïve T cells; 2] whether they differ in their ability to activate
antigen-experienced or -primed T cells; and 3] whether these lung CD11c+ APC populations differ
from the splenic CD11c+ APCs which have been commonly used for understanding APC biology.
Results:  CD11c+ APCs from the alveolar space, lung parenchyma, and the spleen display
differential co-stimulatory molecule expression and cytokine responsiveness upon stimulation.
Alveolar space APCs are weak activators of naïve T cells compared to lung parenchymal and splenic
CD11c+ APC populations. However, alveolar space APCs are able to potently activate the in vivo
microbial antigen-primed T cells to a similar extent as lung parenchymal and splenic APCs.
Conclusion: Together our findings indicate that alveolar CD11c+ APCs have a specialized T cell-
activating function, capable of activating antigen-primed, but not naïve, T cells whereas lung
CD11c+ APCs are capable of activating both the naïve and antigen-primed T cell populations.
Background
The lung is a mucosal organ that is continuously exposed
to the outside environment, rendering it one of the major
sites of primary bacterial and viral infections. It is gener-
ally believed that upon pathogenic microbial invasion,
antigen presenting cells (APCs) such as dendritic cells
(DCs) and macrophages present in the lung intercept
these microbes and participate in the initiation of ensuing
innate and adaptive T cell responses. However, the lung is
divided into two major compartments: the alveolar space
and the parenchyma. In the steady state, the vast majority
of cells in the alveolar space, which can be harvested by
Published: 13 August 2008
BMC Immunology 2008, 9:48 doi:10.1186/1471-2172-9-48
Received: 9 April 2008
Accepted: 13 August 2008
This article is available from: http://www.biomedcentral.com/1471-2172/9/48
© 2008 Kugathasan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Immunology 2008, 9:48 http://www.biomedcentral.com/1471-2172/9/48
Page 2 of 12
(page number not for citation purposes)
bronchoalveolar lavage (BAL), are alveolar macrophages
(AMs), which are the first line of leukocytes in the lung
taking up incoming microbes or microbial antigens [1-4].
On the other hand, the lung parenchymal tissue including
the airway epithelium comprises a variety of APC types
including DCs and B cells [5,6]. Traditionally, it is the
lung DCs that are deemed the most critical to transporting
antigens from tissue to the local draining lymph nodes to
activate naïve T cells [7,8].
The issue regarding whether alveolar macrophages are
capable of naïve T cell activation has remained controver-
sial [2,4,9-15]. While AMs are generally thought to be
poor T cell stimulators or even immunosuppressive as
shown in some studies [11,16,17], they have also been
shown to be able to activate certain T cell subsets [9]. The
possibility for AMs to act as functional APCs is further
supported by the evidence that macrophages could
migrate to the local lymphoid tissues or acquire DC char-
acteristics [13,18-20]. Furthermore, local non-migratory
residential APCs including macrophages are thought to
play a role in presenting antigen to and activating antigen-
experienced or effector/memory T cells within the lung
parenchyma [21]. In comparison, there has been well-
established evidence to support an indisputable role by
lung parenchymal DCs in transporting antigens to the sec-
ondary lymphoid tissue and activating naïve T cells [22-
24]. However, several important questions remain to be
elucidated: 1] to which extent the alveolar space CD11c+
APCs and lung parenchymal CD11c+ APCs differ in their
phenotype and ability to activate naïve T cells; 2] whether
they differ in their ability to activate antigen-experienced
or -primed T cells; and 3] whether these lung CD11c+ APC
populations differ from the splenic CD11c+ counterparts
which have been often used for understanding APC biol-
ogy. The lack of such knowledge is due to the fact that the
majority of studies have thus far examined the pheno-
types and functions of APC populations from various tis-
sue compartments in isolation [25-28] or the direct
comparative studies were carried out by using bone mar-
row- or spleen-derived macrophages and DCs [29-31].
Emerging evidence suggests that the knowledge generated
at one site may not apply to another site as different ana-
tomical locations or tissue microenvironments pro-
foundly influence the phenotype and function of APC
populations [5,32-34]. The knowledge regarding the rela-
tive T cell activation capacities of APCs within different tis-
sue compartments will help us understand the immune
regulatory mechanisms and develop APC-based strategies
for immune manipulation.
In the present study, by using various approaches we have
directly compared the phenotype of alveolar space
CD11c+ APCs and the lung parenchymal CD11c+ APCs
and their capability to activate both naïve and antigen-
primed T cells. We have also compared these lung
CD11c+ APC populations with the splenic CD11c+ APCs.
We report that CD11c+ APCs from the alveolar space,
lung parenchyma, and the spleen display differential co-
stimulatory molecule expression and cytokine responsive-
ness. In addition, alveolar space APCs are poor activators
of naïve T cells compared to lung parenchymal and
splenic CD11c+ APC populations. However, alveolar
APCs are able to potently activate the in vivo microbial
antigen-primed T cells to a similar extent as lung paren-
chymal and splenic CD11c+ APCs.
Results
Freshly isolated CD11c+ APC populations from the 
alveolar space, lung parenchyma, and spleen express 
differential levels of co-stimulatory molecules
Alveolar macrophages (AMs) in the lung are well known
to express the cell surface marker CD11c which is com-
monly expressed by murine DC populations in other tis-
sue sites such as the lung interstitium and spleen [22,35-
38], thus resulting in the vast majority (> 95%) of AMs in
naïve lungs being CD11c+ [39,40]. This fact has allowed
us to conveniently isolate AM and lung interstitial and
splenic DC populations based on CD11c selection and
subsequently compare their phenotypes and functions.
Thus, by using this approach, we first compared the co-
stimulatory molecule expression of CD11c+ APC popula-
tions freshly isolated by MACS purification from the alve-
olar space, lung parenchyma and the spleen as expression
of co-stimulatory molecules on APCs is critical to T cell
activation. Since the alveolar space APCs were isolated
first by bronchoalveolar lavage (BAL) before subjecting to
MACS purification, these APCs were also called BAL APCs.
We found that similar percentages of BAL and lung paren-
chymal CD11c+ APCs expressed major histocompatibility
class II (MHC II) molecules, B7.1 and CD40 molecules on
their surface (Figure 1A). In comparison, a greater propor-
tion of splenic CD11c+ APCs expressed these molecules
(Figure 1A). However, the mean fluorescence intensity
(MFI) reveals that on average the amount of co-stimula-
tory molecules present on the BAL CD11c+ cells is much
less than on the lung parenchymal CD11c+ cells while the
splenic CD11c+ cells expressed the greatest MFI of these
molecules (Figure 1B). Thus, CD11c+ cell populations
located in different anatomical compartments express dif-
ferential levels of co-stimulatory molecules on their sur-
face, suggesting that they may also have differential
functions or effector activities.
Differential levels of cytokine production by CD11c+ APC 
populations from the alveolar space, lung parenchyma 
and spleen upon stimulation
Having observed differential co-stimulatory molecule
expression by CD11c+APCs from the BAL, lung paren-
chyma and the spleen, we next evaluated the cytokineBMC Immunology 2008, 9:48 http://www.biomedcentral.com/1471-2172/9/48
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responses of these APC populations. To this end, cells
were cultured for 48 h with either LPS or mycobacterial
antigens. Using ELISA, we elected to look at the pro-
inflammatory cytokine TNF-α and the type 1 cytokine IL-
12 as the both are considered the major players in the acti-
vation and regulation of type 1 T cell responses and the
maintenance of granulomatous responses against intrac-
ellular pathogens [41]. While BAL CD11c+ APCs pro-
duced significantly greater amounts of TNF-α in response
to both LPS and Mtb-CF stimulation than both lung
parenchymal CD11c+ and splenic CD11c+ APCs (Figure
2A), splenic CD11c+ APCs produced the least amounts of
this cytokine. On the other hand, lung parenchymal APCs
produced the greatest amounts of IL-12 in response to
both LPS and Mtb-CF, whereas airway and spleen APCs
produced barely detectable amounts of IL-12 (Figure 2B).
These APC populations all produced undetectable levels
of anti-inflammatory cytokine IL-10 (data not shown).
Thus, in addition to phenotypic differences, airway lumi-
nal, lung parenchymal, and splenic CD11c+ APCs pro-
duce differential levels of type 1 cytokines in response to
LPS or mycobacterial antigens stimulation.
Alveolar space CD11c+ APCs are poor stimulators of 
allogeneic T cells compared to splenic CD11c+ APCs
Since we observed differential co-stimulatory molecule
expression and cytokine responses by CD11c+ cells from
the three tissue compartments, we set out to examine and
compare their capacity in T cell activation. We first exam-
ined their ability to stimulate allogeneic T cell prolifera-
tion. To this end, a mixed leukocyte reaction (MLR) was
carried out by using CD11c+ cells from the BAL, lung
parenchyma, and spleen of C57Bl/6 mice in a co-culture
system at different ratios with CFSE labelled T cells iso-
lated from Balb/c spleens. A ratio of 1:5 APC vs. T cells
yielded the optimal amount of proliferation in our sys-
tem. In keeping with their similar levels of MHC class I
and II molecule expression (Figure 1), both BAL and lung
interstitial APCs stimulated similar MLR (Figure 3). In
comparison, the splenic APCs triggered greater levels of
MLR (Figure 3), consistent with their higher levels of
Co-stimulatory molecule expression of CD11c+ APCs from the alveolar space, lung parenchyma, and the spleen Figure 1
Co-stimulatory molecule expression of CD11c+ APCs from the alveolar space, lung parenchyma, and the 
spleen. Surface co-stimulatory molecule expression was analyzed by gating on CD11c+ cell populations by FACS. A, repre-
sentative histograms showing the percentage of co-stimulatory molecules expression by CD11c+ cells. Solid lines, specific 
staining; shaded histograms, appropriate isotype controls. B, Average Mean Fluorescent Intensity (MFI) of co-stimulatory mark-
ers. Data are representative of three independent experiments.
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expression of MHC and co-stimulation molecules (Figure
1).
Differential levels of naïve antigen-specific transgenic T 
cell activation by peptide-loaded CD11c+ APC 
populations from the alveolar space, lung parenchyma 
and spleen
Following the observation that splenic, lung parenchymal
and BAL CD11c+ cells were able to activate allogeneic T
cells differentially, we next examined whether these APC
populations differed in their capacity to activate naïve
antigen-specific transgenic T cells. To this end, CD8 T cells
from the TCR transgenic OT-I mice were purified and
labeled with CFSE and then co-cultured with CD11c+ cell
populations purified from the BAL, lung parenchyma, and
spleen which were prior pulsed with CD8+ T cell OVA
peptide SIINFEKL. We found that BAL APCs (1.6%) were
the poorest naïve CD8+ T cell stimulators compared to
lung parenchymal (7.8%) and splenic APCs (29.8%) (Fig-
ure 4A). To examine transgenic CD4 T cell responses,
APCs from the BAL, lung interstitium and spleen were
pulsed with a CD4 T cell OVA peptide before co-culturing
with OT-II transgenic CD4 T cells in vitro. Again, the BAL
APCs stimulated only a lower level of OT-II CD4 T cell
proliferation (13.9%) than lung interstitial APCs whereas
splenic APCs stimulated the highest level of OT-II T cell
responses (47.4%) (Figure 4B).
Differential levels of naïve antigen-specific transgenic T 
cell activation by virally-infected CD11c+ APC populations 
from the alveolar space, lung parenchyma and spleen
Since the above approach utilized antigenic peptides to
directly load APCs, it represents a rather innocuous, artifi-
cial way to prepare APCs for antigen presentation and T
cell activation. To further evaluate and compare antigen
processing and presentation and T cell activation by
CD11c+ APC populations from the BAL, lung paren-
chyma and the spleen, we set out to infect CD11c+ APC
populations by using a recombinant adenovirus express-
ing OVA, a process that would involve natural infection,
intracellular antigen processing and MHC pathway target-
ing and subsequent antigen presentation. To this end,
CD8+ T cells from OT-I transgenic mice and CD4+ T cells
from OT-II transgenic mice were purified and CFSE-
labeled and then co-cultured with varying numbers of
APCs from the BAL, lung, and the spleen while keeping
the T cell number the same. A ratio of 1:2 of APCs vs. T
cells elicited the optimal amount of proliferation in our
system. Compared to the direct peptide loading approach,
virally transduced APCs in general stimulated a lower
level of transgenic CD8 and CD4 T responses (Figure 5A/
B). However, the T cell stimulation profile by virally trans-
duced APCs from the BAL, lung parenchyma and spleen
recapitulated that by peptide-loaded APCs (Figures 4A/B
and 5A/B). These results thus together reaffirm our above
observations that BAL CD11c+ cells have the weakest abil-
Proinflammatory cytokine production by freshly isolated CD11+ APCs upon stimulation Figure 2
Proinflammatory cytokine production by freshly isolated CD11+ APCs upon stimulation. Freshly isolated 
CD11c+ APCs from the BAL, lung parenchyma, and the spleen were cultured for 48 h with LPS or mycobacterial antigens 
(Mtb-CF). Culture supernatants were measured for TNF-α (A) and IL-12 (B) by ELISA. Results are representative of three 
independent experiments and are presented as mean ± SD. *p < 0.05 compared to the corresponding lung data. #p < 0.05 
compared to the corresponding spleen data.
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ity to activate naïve antigen specific T cells compared to
their lung parenchymal and splenic counterparts.
Alveolar space CD11c+ APCs, similar to lung interstitial 
and splenic APCs, can lead to potent antigen recall 
responses of in vivo primed endogenous T cells
The above approaches only allowed us to analyze the
responses of naïve transgenic CD4+ and CD8+ T cells
stimulated by CD11c+ APCs in vitro. To investigate
whether APC populations from the three different com-
partments may differ in their capability to activate the nat-
ural T cells that were spontaneously activated during the
course of infection, we compared the CD11c+ cell popu-
lations from the BAL, lung parenchyma and the spleen for
their ability to re-activate mycobacterial antigen-specific,
IFN-γ-releasing type 1 T cells that naturally developed in
vivo during mycobacterial infection. This is a particularly
relevant question given that the alveolar space APCs
largely made up by macrophages are the primary cellular
targets of mycobacterial infection in the lung [42] and that
these cells were previously shown to be able to activate
certain T cells in mycobacterial infection [9]. To this end,
mice were infected via the airway with live mycobacterial
BCG and in vivo primed CD4+ and CD8+ T cells were iso-
lated from the spleen. These T cells were then co-cultured
with the CD11c+ cells freshly isolated from naïve mouse
alveolar space, lung parenchyma, and spleen that were
either soluble mycobacterial antigen-loaded or live myco-
bacterium-infected in vitro (Figure 6 diagram). Mycobac-
terial antigen-specific recall activation of T cells was
measured by evaluating IFN-γ secreting cells in an ELIS-
POT assay. Contrast to their inability to markedly activate
naïve transgenic T cells, BAL CD11c+ APCs activated T
cells, particularly CD4 T cells, to a similar extent as the
lung parenchymal and splenic APCs (Figure 6A/B). In
general, soluble mycobacterial antigen loading of APCs
led to higher levels of CD4 T cell activation than live
mycobacterial infection. We observed a greater frequency
of antigen-specific type 1 CD4 T cells than CD8+ T cells
(Figure 6A/B), which is in agreement with the current
understanding that mycobacterial infection activates pre-
dominantly a type 1 CD4 T cell response [43]. These data
suggest that alveolar CD11c+ APCs can activate antigen
experienced T cells to a similar extent as lung parenchymal
and splenic CD11c+ APCs.
Discussion
Antigen presenting cells play a pivotal role in initiating T
cell responses against foreign pathogens. Their role
becomes even more important at mucosal sites of the
body including the skin, gut and lung where maximal
microbial encounter occurs. Despite the recognized
importance of APCs in eliciting T cell responses in the
lung, our understanding regarding the relative T cell acti-
vation capacity of alveolar space (BAL), lung parenchy-
mal, and splenic CD11c+ APCs still remains largely to be
understood due to the lack of side-by-side comparative
studies. In the present study we have evaluated and com-
pared the phenotype of BAL, lung parenchymal, and
splenic CD11c+ APC populations and their capabilities to
activate both naïve and antigen-primed T cells. We report
here that CD11c+ APCs from the BAL, lung parenchyma,
and the spleen display differential co-stimulatory mole-
cule expression and cytokine responsiveness. Further-
more, BAL CD11c+ APCs are incapable of markedly
activating naïve T cells in contrast to lung parenchymal
and splenic CD11c+ APC populations. However, these
alveolar space CD11c+ APCs are able to potently activate
the in vivo microbial antigen-primed T cells to a similar
extent as lung parenchymal and splenic CD11c+ APCs.
The surface marker CD11c has been widely used for iden-
tifying and/or purifying antigen presenting DCs and mac-
rophages [22,35-40,44] although it may also be expressed
by other leukocyte subsets [37]. We believe that the
majority of alveolar space CD11c+ APCs isolated by lavag-
ing naïve mouse lung we used in our study are alveolar
macrophages, different from the BAL of infected lungs
which may contain heterogenous CD11c+ APC popula-
tions. This conviction is also supported by other pub-
lished studies demonstrating that the vast majority (>
96%) of BAL CD11c+ cells are alveolar macrophages
[39,40]. However, it is likely that a small fraction of these
Allogeneic T cell proliferation stimulated by CD11c+ APCs  isolated from BAL, lung parenchyma and spleen Figure 3
Allogeneic T cell proliferation stimulated by CD11c+ 
APCs isolated from BAL, lung parenchyma and 
spleen. Freshly isolated BAL, lung, and splenic CD11c+ APC 
populations from C57Bl/6 mice were co-cultured with CFSE-
labelled splenic T cells from Balb/c mice. The extent of allo-
geneic T cell proliferation was analyzed by FACS. Values 
shown are subtracted from appropriate controls and are the 
means ± SD of triplicate samples, representative of two inde-
pendent experiments.
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naïve BAL CD11c+ APCs may be DCs as it has previously
been shown that a very minute fraction (< 2%) of BAL
CD11c+ APCs are DCs [39]. On the other hand, the lung
interstitial CD11c+ APCs used in this study are most likely
a mixture of pulmonary DCs and macrophages. It is note-
worthy that although the use of additional surface mark-
ers such as F4/80 and DEC-205 in conjunction with
CD11c may aid in differentiating macrophages from DCs
[22,35-40,44], it has been reported that F4/80 can also be
expressed by DCs [37] and that DEC205 can also be
expressed by pulmonary macrophages [45]. Our findings
highlight that the tissue microenvironment or the ana-
tomical location influences the function of APCs. Von
Garnier et al. have shown that dendritic cells within the
main conducting airway tissue (the trachea and main
bronchi) and the lung parenchyma differ in their capacity
to activate OVA-specific CD4+ T cell activation [5]. Simi-
larly, we have shown that the CD11c+ APCs from the alve-
olar space are weak allogenic stimulators and are
incapable of activating naive OVA-specific CD4+ and
CD8+ T cells contrast to lung parenchymal and splenic
CD11c+ APCs. However, we demonstrate that alveolar
space CD11c+ APCs were able to activate antigen-primed
type 1 CD4+ and CD8+ T cells to a similar extent as the
lung parenchymal and splenic CD11c+ APCs. To our
knowledge, our current study is the first to have directly
compared alveolar space, lung parenchymal, and splenic
CD11c+ APCs for their phenotypes and capacities to acti-
vate both naïve and primed T cells and concluded that
alveolar space or BAL CD11c+ APCs are much poorer acti-
vators of naïve T cells than those isolated from the lung
parenchyma and the spleen. This observation is in general
agreement with the finding that alveolar macrophages
may be immunosuppressive [25]. The fact that contrast to
Antigen-specific transgenic T cell activation by peptide-pulsed CD11c+ APCs from BAL, lung parenchyma and spleen Figure 4
Antigen-specific transgenic T cell activation by peptide-pulsed CD11c+ APCs from BAL, lung parenchyma and 
spleen. CD11c+ APC populations isolated from BAL, lung and spleen were pulsed with OVA OT-I (SIINFEKL) or OT-II pep-
tide and co-cultured for 48 hours with CFSE-labelled OT-I CD8+ T cells or for 72 hours with CFSE-labelled OT-II CD4+ T 
cells. Transgenic T cell proliferation was analyzed by FACS. A, OT-I CD8 T cell proliferation. B, OT-II CD4 T cell proliferation. 
Representative histograms of T cell proliferation are shown. The average T cell proliferation rates are shown in bar graphs 
after subtracting from appropriate controls. Results are presented as mean ± SD of triplicate samples. *p < 0.05.
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the relatively strong naïve T cell-activating capability of
lung parenchymal and splenic CD11c+ APCs, BAL
CD11c+ APCs is a poor activator of naïve T cells, suggests
that a small fraction of DCs, if any, present in the BAL
CD11c+ APC population plays a negligible role. However,
we cannot completely rule out the possibility that under
steady state conditions (naïve), the T cell activating capac-
ity of contaminating DCs (if any) may be suppressed by
the alveolar macrophages and with antigen-primed T
cells, these BAL DCs may overcome the inhibitory effect of
the alveolar macrophages to more readily activate anti-
gen-primed T cells which may have decreased activation
threshold. However, we feel that this is unlikely since the
lung interstitial or splenic CD11c+ APCs activated anti-
gen-primed T cells to a similar extent as they did to naïve
T cells. It has also been demonstrated that alveolar macro-
phages can indeed act as accessory cells for mycobacterial
antigen experienced γδ T cells [9]. Our results suggest that
naïve T cells and antigen-primed effector T cells may have
differential activation requirements. Furthermore, our
results imply that alveolar macrophages and lung intersti-
tial APCs play a distinct role in the early phase of T cell
priming and activation with the latter playing the most
critical role. However, during the effector phase of T cell
responses, both alveolar macrophages and lung APCs
could go on to present antigens and activate antigen-
primed effector T cells. Given the large number of alveolar
macrophages at the site of infection, these APCs may play
an even greater role than DCs in effector T cell activation
within the respiratory tract. We have recently demon-
strated that airway luminal T cells are critical to immune
protection against intracellular bacterial infection such as
pulmonary tuberculosis [46,47].
Antigen-specific transgenic T cell activation stimulated by virally transduced CD11c+ APCs from BAL, lung parenchyma and  spleen Figure 5
Antigen-specific transgenic T cell activation stimulated by virally transduced CD11c+ APCs from BAL, lung 
parenchyma and spleen. CD11c+ APC populations isolated from BAL, lung and spleen were infected with AdOVA and co-
cultured either for 48 hours with CFSE-labelled OT-I CD8 T cells or for 72 hours with CFSE-labelled OT-II CD4 T cells. The 
rate of transgenic T cell proliferation was analyzed by FACS. A, OT-I CD8 T cell proliferation. B, OT-II CD4 T cell prolifera-
tion. Representative histograms of T cell proliferation are shown. The average T cell proliferation rates are shown in bar 
graphs after subtracting from appropriate controls. Results are presented as the mean ± SD of triplicate samples. *p < 0.05.
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Moreover, the ability of APCs to activate T cells is related
to their co-stimulatory molecules expression as demon-
strated by studies in which T cell proliferation is strongly
inhibited by abrogation of either CD80 (B7.1) or CD86
[48,49], signifying that CD11c+ cell populations from the
alveolar space, lung parenchyma, and the spleen all have
the capacity to activate T cells since they all express MHC
II and the co-stimulatory molecules B7.1 and CD40,
albeit at different levels. This may explain the differential
activation of naïve T cells by BAL, lung parenchymal and
splenic CD11c+ APCs. In general, we observed relatively
robust responses of both transgenic CD8 and CD4 T cell
responses to the APCs loaded with OVA peptides. This is
likely due to the efficiency of direct MHC loading and
presentation of OVA peptides, particularly the CD8 T cell
peptide. In comparison, the transgenic CD4 T cell
responses to the APCs infected with an adenovirus
expressing OVA protein were considerably lower than
CD8 T cell responses. This is in accord with the under-
standing that virus infection preferentially target the MHC
I pathway (CD8 T cell activation). This observation was
noted across all three CD11c+ APC populations, suggest-
ing that despite coming from different anatomical sites,
these CD11c+ APC populations process viral antigens in a
similar manner for naïve T cell activation. We have also
reported here that freshly isolated BAL CD11c+ cells pro-
duce significantly greater levels of the pro-inflammatory
cytokine TNF-α than their parenchymal and splenic coun-
Ex vivo activation of in vivo mycobacterium-primed natural T cells by CD11c+ APCs from BAL, lung parenchyma and spleen Figure 6
Ex vivo activation of in vivo mycobacterium-primed natural T cells by CD11c+ APCs from BAL, lung paren-
chyma and spleen. CD11c+ APC populations were isolated from BAL, lung parenchyma and the spleen and pulsed with M.tb 
CF protein or infected with live mycobacteria. APCs were then co-cultured with CD4+ or CD8+ T cells that were purified 
from the mice that were infected by live mycobacteria for 17 days (diagram). Cells were co-cultured for 24 h and IFN-γ-secret-
ing T cells were determined by ELISPOT assay. A, IFN-γ-secreting CD4+ T cells. B, IFN-γ-secreting CD8+ T cells. Data are 
expressed as the mean value ± SD of triplicate samples and representative of two independent experiments. ‡p < 0.05 com-
pared to the corresponding mycobacterial BCG-infected APCs; #p < 0.05 compared to the corresponding spleen data.
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terparts, which is in agreement with the current under-
standing that alveolar macrophages are a great source of
TNF-α [50]. However, parenchymal CD11c+ APCs pro-
duce a greater amount of the type 1 cytokine IL-12 com-
pared to BAL CD11c+ APCs, which is in agreement with
the stronger ability of the parenchymal CD11c+ APCs to
activate naïve T cells. This disparate levels of TNF-α and
IL-12 released by BAL and lung parenchymal CD11c+
APCs to LPS or mycobacterial antigens may be due to their
use of distinct TLRs and differential TLR expression
[29,51,52], which is likely influenced by the different tis-
sue microenvironments [53,54]. IL-10, a potent Th1
opposing cytokine, was undetectable in our CD11c+ APC
cultures from all the three compartments, suggesting that
this cytokine does not account for the differential type 1
cytokine responses seen in our study. Our study reinforces
that the knowledge generated by using APCs from one tis-
sue site cannot be generalized and applied for all due to
the heterogeneity of APCs tailored to different anatomic
locations and specialized functions.
In conclusion, we have provided the evidence that the
CD11c+ APC populations existing within the alveolar
space, lung parenchyma, and the spleen differ much in
their co-stimulatory molecule expression, cytokine
responsiveness, and antigen presentation and T cell acti-
vation capacities. Furthermore, we have shown that alve-
olar space macrophages are poor activators of naïve T cells
but can activate antigen experienced T cells to a similar
extent as lung parenchymal and splenic CD11c+ APC
populations. The findings presented in this study thus
enhance our understanding about the relative capacity of
alveolar space, lung parenchymal and splenic CD11c+
APCs to activate T cells, and further highlights the impor-
tance of tissue microenvironment influencing antigen
presenting function of different APC populations.
Conclusion
Our study suggests that alveolar CD11c+ APCs have a spe-
cialized T cell-activating function, capable of activating
antigen-primed, but not naïve, T cells whereas lung
CD11c+ APCs are capable of activating both the naïve and
antigen-primed T cell populations.
Methods
Mice
Six- to 10-wk-old female C57Bl/6 and Balb/c mice were
purchased from Harlan Laboratories. Female/male OT-I
and OT-II transgenic mice were bred at McMaster Univer-
sity Central Animal Facility. All mice were housed in a spe-
cific pathogen-free level B facility. All experiments were
conducted in accordance with the McMaster Animal
Research Ethics board.
Mycobacterial preparation
Mycobacterium bovis BCG (Connaught strain) was pre-
pared as previously described in our lab [55,56]. Briefly,
BCG was grown in Middlebrook 7H9 broth (Difco) sup-
plemented with Middlebrook OADC enrichment (Invit-
rogen), 20% glycerol, and 0.05% Tween 80 for 10 to 15
days, and samples were then divided into aliquots and
stored at -70°C. BCG was washed twice with phosphate-
buffered saline (PBS) containing 0.05% Tween 80 and
resuspended in PBS. It was then passed through a 27-
gauge needle 10 times to disperse clumps and then
diluted with PBS to the desired concentration before use.
Isolation of CD11c+ APCs from the alveolar space, lung 
parenchyma, and spleen
Naïve mice were sacrificed by bleeding the abdominal ves-
sels. Mouse lungs were then removed aseptically and lav-
aged with PBS to isolate bronchoalveolar lavage (BAL)
cells from the alveolar space. The mouse lung was exhaus-
tively lavaged 5 times to a total volume of 1.8 ml PBS
through a polyethylene cannulated into the trachea to
ensure maximal cell recovery. Extra effort was made to
ensure that only the lung parenchyma was collected and
any trachea and main bronchi including all associated
hilar lymph nodes were removed. The lavaged lungs and
the spleens were infused with collagenase type 1 (Sigma)
and then cut up into small pieces and subsequently incu-
bated in collagenase at 37°C; 1 hour for lungs and 45
minutes for spleens. The collagenase digested lungs and
spleens were then passed through 100 μm cell strainers,
and a 3 ml needle plunger was used to mash the cells
through the strainer. After red blood cell lysis with a
mouse erythrocyte lysing kit (R&D Systems), lungs and
spleens were filtered and resuspended in complete RPMI
(cRPMI) media (RPMI 1640 supplemented with 10% fetal
bovine serum, 1% penicillin-streptomycin, 1% L-
glutamine). Cells were counted, and viability (always >
90%) was measured by trypan blue exclusion. Depending
on the experiment, BAL, lung, and spleen cells from a
number of mice were pooled and incubated with CD11c
microbeads (Miltenyi biotec) according to the manufac-
turer's instructions. CD11c labelled cells were then passed
through an MS column on the OctoMACS separator
(Miltenyi biotec). Samples were run through MACS sepa-
ration columns twice to achieve higher purity. Cells were
counted, and viability was measured by trypan blue exclu-
sion. Purity of cell preparations were determined using
flow cytometry, and the purity of CD11c+ populations
was consistently > 90%.
Cell surface immunostaining and FACS analysis
All monoclonal antibodies (MAbs) used were purchased
from BD Pharmingen. Immunostaining and FACS were
carried out as previously described [55,56]. Briefly, cells
were blocked for non-specific binding of their Fc receptorsBMC Immunology 2008, 9:48 http://www.biomedcentral.com/1471-2172/9/48
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with anti-CD16/CD32 antibodies for 15 min and then
stained for 30 min on ice with the appropriate combina-
tions of fluorochrome-conjugated MAbs. Fluorochrome-
conjugated MAbs to CD11c, B7.1, CD40, MHC Class II,
CD3, CD4, and CD8 were used. Appropriate Isotype con-
trols were used for each antibody. The data was collected
with the LSRII (BD Biosciences) flow cytometer using
FACSDiva software and analyzed with Flowjo software.
Cell culture and ELISA
Purified CD11c+ APCs (0.1 × 106/well) from the alveolar
space, lung parenchyma, and spleen were seeded into 96-
well flat bottom plate and cultured at 37°C and 5% CO2
with or without antigen stimulation. The antigens used
for stimulation were LPS (1 ng/well) and Mycobacterium
tuberculosis Culture Filtrate proteins (Mtb-CF) (2 μg/well).
Cells were cultured in a total volume of 250 μl of cRPMI.
The culture supernatants were collected at 48 h and stored
at -20°C until cytokine measurement. TNF-alpha and IL-
12p40 concentrations were measured by using ELISA kits
(R&D systems).
Mixed leukocyte reaction (MLR)
MLR was carried out as previously described [53]. Alloge-
neic splenic T cells were isolated from naïve Balb/c mice
using CD4 and CD8 positive isolation kits (both from
Miltenyi biotec) according to the manufacturer's protocol
and pooled. T cells were then labelled with 5 μM CFSE
(Molecular Probes) in PBS supplemented with 5% FBS
and then washed three times after staining. 5 × 105 CFSE
labelled T cells were co-cultured with a varying number of
C57Bl/6 CD11c+ APC populations from the alveolar
space, lung parenchyma, and spleen in 96-well culture
plate at 37°C for 96 hours. T cell proliferation was exam-
ined by flow cytometric analysis of CFSE dilution as pre-
viously described [57].
In vitro transgenic T cell proliferation Assay
CD4 T cells were MACS purified from OT-II transgenic
mice and CD8 T cells were purified from OT-I transgenic
mice using the CD4+ and CD8+ T cell isolation kits,
respectively, according to the manufacturer's instructions
(Miltenyi biotec). T cells were labelled with 5 μM CFSE
(Molecular Probes) and washed 3 times with PBS supple-
mented with 5% FBS and resuspended in cRPMI. 5 × 105
CFSE labelled OT-II T cells were co-cultured with varying
numbers of C57Bl/6 APC populations from BAL, lung,
and spleen that were pre-pulsed with CD4 or CD8 OVA
peptide (0.1 ng/μl) for 1 hour. Unpulsed CD11c+ cells co-
cultured with T cells and T cells cultured with no CD11c+
APCs were set up in parallel as controls. CD8+ and CD4+
T cell proliferations were examined 48 and 72 hours after
culture by flowcytometric analysis of CFSE dilution,
respectively. In some experiments, APCs were pre-infected
with an adenovirus expressing the OVA protein (AdOVA)
(100 pfu/cell) overnight and then co-cultured with OT-I
or OT-II T cells. An adenoviral vector (Addl70-3) infected
CD11c+ cells and uninfected CD11c+ cells were used as
controls in these experiments.
Ex vivo T cell activation assay
In vivo mycobacterium-primed CD4+ T cells and CD8+ T
cells were MACS-purified as described above from the
spleens of mice that had been infected with live M. bovis
BCG (106 cfu) for 17d as previously described [55]. 0.4 ×
106 T cells were co-cultured with 4000 naïve BAL, lung,
and spleen CD11c+ APC populations that were infected
with either BCG (2 cfu/cell) or stimulated with Mtb-CF (2
ug/well) or just culture media (no stimulus). IFN-γ secre-
tion ELISPOT was carried out as previously described [58].
Briefly, isolated CD4+ and CD8+ T cells (0.4 × 106) were
seeded into a 96-well PVDF microplate (Millipore Corpo-
ration) pre-coated overnight with a mouse IFN-γ capture
antibody (R&D system). Cells were incubated for 24 h
and then washed and incubated with a detection antibody
at 4°C overnight. The plate was developed by using stand-
ardized streptavidin-conjugated alkaline phosphatase and
chromogen method (R&D system). The number of IFN-γ-
releasing cells was determined by using an ELISPOT
reader (CTL Cellular Technology Ltd).
Statistical analysis
All statistical analyses were performed using unpaired,
two-tailed student's t test with Excel spreadsheet software
(Microsoft). Values of p < 0.05 were considered statisti-
cally significant.
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